CK2 inhibitors can reduce the release of TNF, IL-6, and VEGF cytokine in cancer cells (73).CK2 inhibitors can suppress the production of tumor-derived factors (TDF) to modulate immune cells development and promote tumor regression (69). Here, TNF is linked to neoplasm.